Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

The New England journal of medicine - 5 Feb 2009

Tol Jolien, Koopman Miriam, Cats Annemieke, Rodenburg Cees J, Creemers Geert J M, Schrama Jolanda G, Erdkamp Frans L G, Vos Allert H, van Groeningen Cees J, Sinnige Harm A M, Richel Dirk J, Voest Emile E, Dijkstra Jeroen R, Vink-Börger Marianne E, Antonini Ninja F, Mol Linda, van Krieken Johan H J M, Dalesio Otilia, Punt Cornelis J A

Abstract excerpt

BACKGROUND: Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. METHODS: We randomly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Deoxycytidine

Share to Fluorouracil

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Treatment Failure

Source

Identifiers

PMID: 19196673
DOI: 10.1056/NEJMoa0808268

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.PMID 19196673Read ↗

Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.Semantic proximity Read ↗

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.Semantic proximity Read ↗

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.Semantic proximity Read ↗

A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.Semantic proximity Read ↗

Cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.Semantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.